Prosecution Insights
Last updated: April 19, 2026
Application No. 18/268,830

A Hemostatic Tissue Adhesive Composition Comprising An NCO-Terminated Urethane Preprolymer

Non-Final OA §103§112
Filed
Jun 21, 2023
Examiner
LEONARD, MICHAEL L
Art Unit
1763
Tech Center
1700 — Chemical & Materials Engineering
Assignee
UNIVERSITE DE STRASBOURG
OA Round
1 (Non-Final)
64%
Grant Probability
Moderate
1-2
OA Rounds
3y 3m
To Grant
72%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allow Rate
839 granted / 1319 resolved
-1.4% vs TC avg
Moderate +8% lift
Without
With
+8.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
64 currently pending
Career history
1383
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
50.5%
+10.5% vs TC avg
§102
19.2%
-20.8% vs TC avg
§112
18.7%
-21.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1319 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Objections Claim 9 is objected to because of the following informalities: delete “at temperature” in line 4. Appropriate correction is required. Claim 14 is objected to because of the following informalities: delete “the diisocyanate being selected from the list consisting of…” under a’. Appropriate correction is required. Claim 18 is objected to because of the following informalities: delete “advantageously” in line 10. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3, 11, 13-14, and 16-19 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 3 recites the broad recitation 149 and 560 mgKOH/g, and the claim also recites “advantageously, more advantageously, and in particular” which are narrower statements of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Claim 11 recites the limitation "the molar ratio" in line 1. There is insufficient antecedent basis for this limitation in the claim. In claims 13-14 and 17-19, the limitation “or as obtained by the method of claim 10 or 13;” renders the claims unclear because the methods claimed in claims 10 and 13 are already claimed within the current claim and they fail to further limit the existing claim language already present. The examiner suggests deleting the language. Claim 16 recites the limitation "the molar ratio" in line 2. There is insufficient antecedent basis for this limitation in the claim. Claim 17 recites the limitation "the NCO terminated urethane prepolymer" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. Claim 19 recites the limitation "the NCO terminated urethane prepolymer" in line 3. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1-4, 7 and 9 are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent Pub. No. 2002/0035231 to Whitehouse et al. As to claims 1-4 and 7, Whitehouse discloses a polyurethane comprising the reaction product of polyhydroxyalkanoate derived from ethylene glycol and poly-3-hydroxybutyrate (Examples 1-4) and 1,6-hexamethylene diisocyanate (0022). Whitehouse discloses an NCO:OH ratio of 0.5:1 to 2:1 (0050). At a ratio of 2:1 an NCO-terminated prepolymer would be produced. At the time of filing it would have been obvious to react the isocyanate with the polyhydroxyalkanoate at a ratio of 2:1 to arrive at the presently claimed NCO-terminated prepolymer based on the desired applications of the polyurethane (0057). The molecular weight of polyhydroxyalkanoate ranges from 100 to 750,000 Daltons (0025). The molecular weight in example 1 is 120 g/mol (See formula). As to claim 9 with regard to the viscosity, the Office realizes that all of the claimed effects or physical properties are not positively stated by the reference. However, the reference teaches all of the claimed ingredients. Therefore, the claimed effects and physical properties, i.e. viscosity values would implicitly be achieved by a composite with all the claimed ingredients. If it is the applicants’ position that this would not be the case: (1) evidence would need to be provided to support the applicants’ position; and (2) it would the Office’s position that the application contains inadequate disclosure that there is no teaching as to how to obtain the claimed properties with only the claimed ingredients. Claims 1-4, 7-9, and 13-19 are rejected under 35 U.S.C. 103 as being unpatentable over U.S. Patent No. 5,173,301 to Itoh et al. in view of U.S. Patent Pub. No. 2002/0035231 to Whitehouse et al. As to claims 1-4, 7-8, and 13-19, Itoh discloses tissue adhesive kits comprising an NCO-terminated prepolymer having an NCO content of 1-10% by weight and a chain extender (7:1-10, 8:14-25) such as 1,4-butanediol, polyethylene glycol or polypropylene glycol (Examples 1-2) wherein the prepolymer is derived from a polyester diol (A-4, A-3). Itoh does not expressly disclose the use of the claimed polyhydroxyalkanoate diol. Whitehouse discloses a polyurethane adhesive comprising Whitehouse discloses a polyurethane comprising the reaction product of polyhydroxyalkanoate derived from ethylene glycol and poly-3-hydroxybutyrate (Examples 1-4) and 1,6-hexamethylene diisocyanate (0022). Whitehouse discloses an NCO:OH ratio of 0.5:1 to 2:1 (0050). At a ratio of 2:1 an NCO-terminated prepolymer would be produced. At the time of filing it would have been obvious to replace the polyester diol of Itoh with the polyester diol of Whitehouse to increase biodegradability, improve flexibility and improve hydrophobicity (Abstract). As to claim 9 with regard to the viscosity, the Office realizes that all of the claimed effects or physical properties are not positively stated by the reference. However, the reference teaches all of the claimed ingredients. Therefore, the claimed effects and physical properties, i.e. viscosity values would implicitly be achieved by a composite with all the claimed ingredients. If it is the applicants’ position that this would not be the case: (1) evidence would need to be provided to support the applicants’ position; and (2) it would the Office’s position that the application contains inadequate disclosure that there is no teaching as to how to obtain the claimed properties with only the claimed ingredients. Allowable Subject Matter Claims 5-6, 10-12, and 20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MICHAEL L LEONARD whose telephone number is (571)270-7450. The examiner can normally be reached M - F 7:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Joseph Del Sole can be reached at 571-272-1130. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MICHAEL L LEONARD/ Primary Examiner, Art Unit 1763
Read full office action

Prosecution Timeline

Jun 21, 2023
Application Filed
Oct 27, 2025
Non-Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600811
CROSSLINKING AGENT COMPOSITION FOR WATER-COMPATIBLE RESIN, AND WATER-COMPATIBLE RESIN COMPOSITION
2y 5m to grant Granted Apr 14, 2026
Patent 12583819
POLYTHIOL COMPOSITION, OPTICAL POLYMERIZABLE COMPOSITION, AND OPTICAL PRODUCT
2y 5m to grant Granted Mar 24, 2026
Patent 12583993
RECYCLED POLYOL
2y 5m to grant Granted Mar 24, 2026
Patent 12570789
CURABLE COMPOUND, CURABLE COMPOSITION, AND METHOD FOR PRODUCING CURABLE COMPOSITION
2y 5m to grant Granted Mar 10, 2026
Patent 12565561
HEAT-SHRINKABLE POLYESTER-BASED FILM, HEAT-SHRINKABLE LABEL, AND PACKAGING BODY
2y 5m to grant Granted Mar 03, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
64%
Grant Probability
72%
With Interview (+8.0%)
3y 3m
Median Time to Grant
Low
PTA Risk
Based on 1319 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month